Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Joost C. M. Uitdehaag"'
Autor:
Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus, Martine B. W. Prinsen, Yvonne Grobben, Tessa J. J. de Bitter, Antoon M. van Doornmalen, Janneke J. T. M. Melis, Joost C. M. Uitdehaag, Yugo Narumi, Yusuke Kawase, Jeroen A. D. M. de Roos, Nicole Willemsen-Seegers, Guido J. R. Zaman
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
During the last two decades, kinase inhibitors have become the major drug class for targeted cancer therapy. Although the number of approved kinase inhibitors increases rapidly, comprehensive in vitro profiling and comparison of inhibitor activities
Externí odkaz:
https://doaj.org/article/8a2b28555c90401aa5082f21d4b9f7f8
Autor:
Yvonne Grobben, Jos de Man, Antoon M. van Doornmalen, Michelle Muller, Nicole Willemsen-Seegers, Diep Vu-Pham, Winfried R. Mulder, Martine B. W. Prinsen, Joeri de Wit, Jan Gerard Sterrenburg, Freek van Cauter, Judith E. den Ouden, Anne M. van Altena, Leon F. Massuger, Joost C. M. Uitdehaag, Rogier C. Buijsman, Guido J. R. Zaman
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Indoleamine 2,3-dioxygenase (IDO1) is a key regulator of immune suppression by catalyzing the oxidation of L-tryptophan. IDO1 expression has been related to poor prognosis in several cancers and to resistance to checkpoint immunotherapies. We describ
Externí odkaz:
https://doaj.org/article/67d223be9e3a4daabf3fe18bdc0d30fd
Autor:
Joost C M Uitdehaag, Jeroen A D M de Roos, Antoon M van Doornmalen, Martine B W Prinsen, Jill A P Spijkers-Hagelstein, Judith R F de Vetter, Jos de Man, Rogier C Buijsman, Guido J R Zaman
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0125021 (2015)
The aim of combination drug treatment in cancer therapy is to improve response rate and to decrease the probability of the development of drug resistance. Preferably, drug combinations are synergistic rather than additive, and, ideally, drug combinat
Externí odkaz:
https://doaj.org/article/ef8b227b2f6d4dc1b37d97ccc9facfc1
Autor:
Joost C M Uitdehaag, Jeroen A D M de Roos, Antoon M van Doornmalen, Martine B W Prinsen, Jos de Man, Yoshinori Tanizawa, Yusuke Kawase, Kohichiro Yoshino, Rogier C Buijsman, Guido J R Zaman
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e92146 (2014)
The anti-proliferative activities of all twenty-five targeted kinase inhibitor drugs that are in clinical use were measured in two large assay panels: (1) a panel of proliferation assays of forty-four human cancer cell lines from diverse tumour tissu
Externí odkaz:
https://doaj.org/article/f0dfe06ae41c471a84f2bb2bd66742e5